Table 1.
Clinical features on admission (median/range).
| Bolus (n = 11) | Infusion (n = 10) | Excluded * (n = 13) | |
|---|---|---|---|
| Age (years) | 43 (27–73) | 48 (29–58) | 54 (18–67) |
| Sex F:M | 7 : 4 | 1 : 9 | 10 : 3 |
| Weight (kg) | 50 (45–65) | 48 (40–64) | 50 (35–75) |
| Blood culture positive | 5 | 3 | 6 |
| Pour plate positive | 7 | 4 | 9 |
| Blood culture negative | 0 | 4 | 1 |
| Not-melioidosis | 4 | 2 | 3 |
| Deaths | 9 (82%) | 3 (30%) | 11 (85%) |
| Time to death (h) | 60 (8–240) | 34 (20–624) | 10 (1–624) |
| Serum creatinine (mg dl−1) (Normal range: 0.8–1.7 mg dl−1) | 2.8 (0.8–10.4) | 1.55 (0.9–13) | 3.4 (1–7.2) |
| Estimated creatinine clearance (ml min−1) | 23 (8–94) | 38 (5–69) | 21 (8–50) |
| APACHE II score | 21 (9–27) | 15 (3–23) | 12 (3–24) |
| Temperature (°C) | 39.8 (37.5–41) | 40 (36.5–40.5) | 40.5 (36.9–39.8) |
| Duration of previous symptoms (days) | 8 (4–30) | 14 (5–130) | 10 (3–180) |
*
Eight patients received an infusion and five patients boluses of ceftazidime, exclusion as detailed in methods.